Business
PAOG Confirms CBD Pharmaceutical And Nutraceutical Product Development Presentation Schedule
PAOG Confirms CBD Pharmaceutical And Nutraceutical Product Development Presentation Schedule.
About this update from North American Cannabis Holdings, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Confirms CBD Pharmaceutical And Nutraceutical Product Development Presentation Schedule\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Confirms CBD Pharmaceutical And Nutraceutical Product Development Presentation Schedule\nPR Newswire\nSANDUSKY, Ohio, Feb. 9, 2021\n\n\n\nSANDUSKY, Ohio, Feb. 9, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today confirmed plans to publish a multimedia presentation next week on the company's strategy to expand its nutraceutical product reach.  The company added today that the presentation will also include details on the company's ongoing CBD pharmaceutical developments. \nThe company recently announced plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).  \nThe presentation is scheduled to be published next week on Tuesday, Feb 16th.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\"\nIn addition to PAOG's ongoing efforts to develop a pharmaceutical treatment for COPD, the company has announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).\nLast Thursday, PAOG revealed for the first time a broader nutraceutical development initiative with plans to produce nutraceuticals for additional applications.  The CBD nutraceutical market was valued at $3.8 billion in 2018 forecasted to grow at CAGR of over 18%.\nPAOG plans to establish a revenue stream this year from its nutraceuticals' initiative adding to its recently confirmed a $300,0...